By targeting both inflammatory and bone-resorptive pathways without impairing physiological bone remodeling, sEH inhibition emerges as a promising therapeutic strategy for managing bone loss associated with postmenopausal osteoporosis and periodontitis. The gene discussed is EPHX2; the disease is periodontitis.